Online gift

The flu vaccine, MS and COVID-19

The Belgian Charcot Foundation adheres to the guidelines of our health authorities: or, which are updated when necessary.

The Belgian Charcot Foundation follows the advice of the Belgian Study Group for MS regarding the treatment of MS patients.

Therefore, following recommendations apply:

  1.        The preventive measures provided to the general population ( or do apply even more to patients with MS, especially when treated with disease modifying drugs.
  2.        In patients with MS treated with disease modifying drugs it is recommended:
  •           Interferon-beta (Avonex®, Betaferon®, Rebif®), glatiramer acetate (Copaxone®), teriflunomide (Aubagio®),dimethyl fumarate (Tecfidera®), fingolimod (Gilenya®), natalizumab (Tysabri®): treatment to be continued
  •           Ocrelizumab (Ocrevus®), cladribine (Mavenclad®), alemtuzumab (Lemtrada®), rituximab (Mabthera®): start or redosing of treatment to be postponed if the disease severity/activity of the patient allows
  1.        Persons with MS who are treated with disease modifying drugs and are infected with Covid-19: to stop the ongoing treatment until recovery